CDXSCodexis
About Codexis
Codexis (NASDAQ:CDXS) specializes in developing engineered enzymes for pharmaceutical, bioindustrial, and diagnostic applications. The company's innovative approach to enzyme engineering enables the creation of highly optimized biocatalysts that drive efficiency and cost-effectiveness in drug manufacture, the production of bio-based chemicals, and diagnostic tests. Codexis is focused on leveraging its proprietary CodeEvolver® technology platform to accelerate the development of novel enzymes and to form strategic partnerships and collaborations across various industries. With a strong commitment to sustainability, Codexis aims to contribute to a greener and more sustainable future through its enzyme engineering advancements, targeting objectives that include expanding its enzyme product portfolio and entering new markets.
What is CDXS known for?
Snapshot
Public US
Ownership
2002
Year founded
174
Employees
Redwood City, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Redwood City, US
Products and/or services of Codexis
- Biotherapeutics: Enzyme engineering for developing novel enzymes for therapeutic applications, incorporating protein engineering for targeted drug delivery and disease treatment.
- Codex Biocatalyst Panels: Pre-engineered enzyme kits designed for pharmaceutical and chemical manufacturing, aimed at improving process efficiency and sustainability.
- CodeEvolver: A proprietary platform technology for enzyme optimization, enabling the rapid development of customized solutions for biotherapeutics, fine chemicals, and agrochemicals.
- Custom Enzyme Development Services: Tailored enzyme engineering and development services for unique industrial and pharmaceutical applications, leveraging advanced protein engineering techniques.
- Food and Nutrition Ingredients: Development of enzymes for the production of health-promoting ingredients and processing aids for the food and beverage industry.
- Life Science Tools and Services: Offering enzymes and enzyme-based kits for genomics, drug discovery, and biotherapeutic research, assisting scientific investigation and innovation.
Codexis executive team
- Dr. Alison Moore Ph.D.President, CEO & Director
- Ms. Georgia L. ErbezCFO & Chief Business Officer
- Senator Byron L. Dorgan M.B.A.Consultant
- Dr. Stefan Lutz Ph.D.Chief Scientific Officer
- Ms. Carrie McKimDirector of Investor Relations
- Mr. Britton JimenezSenior Vice President of Sales & Marketing
- Ms. Karen Frechou-ArmijoSenior VP & Head of Human Resources
- Mr. John SchiffhauerSenior Vice President of Intellectual Property